EUCTR2006-002455-33-GB进行中（未招募）1 期
A Phase II, Randomised, Double-blind, Parallel Group Study to Assess the Efficacy of AZD2171 45mg Versus Placebo following 12 Weeks of Treatment in Patients with Metastatic or Recurrent Renal Cell Carcinoma who have had no Previous Anti-VEGF Therapy.
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 105
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1.Provision of informed consent
- •2.Males or females aged 18 years and older
- •3.Histological/cytological confirmation of metastatic or recurrent renal cell clear cell/adenocarcinoma
- •4.One or more measurable lesions at least 10mm in the longest diameter by spiral computed tomography scan or 20mm with conventional techniques (RECIST criteria)
- •5.WHO performance status 0-2
- •6.Life expectancy = 12 weeks
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Previous anti-VEGF therapy
- •2.More than one previous type of immunotherapy
- •3.Prior cytotoxic chemotherapy intended to treat RCC, except 5-FU in combination with immunotherapy
- •4.Surgery scheduled within 12 weeks after entry to the study.
- •5.Treatment with an investigational (non-registered) drug within 30 days prior to starting cediranib.
- •6.Other concomitant anti-cancer therapy (including LHRH agonists), except steroids
- •7.Untreated unstable brain or meningeal metastases. Patients with radiological evidence of stable brain metastases are eligible providing that they are asymptomatic and either do not require corticosteroids or have been treated with corticosteroids, with clinical and radiological evidence of stabilisation at least 10 days after discontinuation of steroids.
- •8.History of other malignancies (except for adequately treated basal or squamous cell carcinoma or carcinoma in situ) within 5 years, unless the patient has been disease free for 2 years and there is a tissue diagnosis of renal cell carcinoma from a target lesion.
- •9.Inadequate bone marrow reserve as demonstrated by an absolute neutrophil count =1.5 x 10(to power 9)/L or platelet count =100 x 10 (to power 9)/L or requiring regular blood transfusions to maintain haemoglobin >9g/dL
- •10.Serum bilirubin = 1.5 x ULRR except in the case of known Gilbert's syndrome
- •11.ALT or AST = 2.5 x ULRR. If liver metastases are present, ALT or AST > 5 x ULRR
- •12.Serum creatinine > 1.5 x ULRR or a creatinine clearance of = 50mL/min calculated by Cockcroft-Gault
- •13.Greater than +1 proteinuria on two consecutive dipsticks taken no less than 1 week apart unless urinary protein < 1.5g in a 24 hr period.
- •14.History of significant gastrointestinal impairment, as judged by the investigator, that would significantly affect the absorption of AZD2171, including the inability to swallow the tablet whole.
- •15.Patients with a history of poorly controlled hypertension or resting blood pressure >150/100 in the presence or absence of a stable regimen of anti-hypertensive therapy.
- •16.Known hypersensitivity to AZD2171 or any of its excipients
- •17.Any evidence of severe uncontrolled diseases e.g. unstable or uncompensated respiratory, cardiac, hepatic or renal disease.
- •18.Unresolved toxicity > CTCAE grade 1 from previous anti-cancer therapy (including radiotherapy) except haematological toxicity (see exclusion 9)
- •19.Mean QTc with Bazetts correction >470msec in screening ECG or history of familial long QT syndrome.
- •20.Significant haemorrhage (>30mL bleeding/episode in previous 3 months) or haemoptysis (>5mL fresh blood in previous 4 weeks)
- •21.Recent (<28 days) major thoracic or abdominal surgery prior to entry into the study, or a surgical incision that is not fully healed
- •22.Pregnant or breast-feeding women or women of childbearing potential with a positive pregnancy test prior to receiving study medication
- •23.Known risk of the patient transmitting HIV or hepatitis B or C via infected blood.
- •24.Involvement in the planning and conduct of the study (applies to both AstraZeneca staff or staff at the study site)
研究者
相似试验
进行中（未招募）
1 期
A Phase II, Randomised, Double-blind, Parallel Group Study to Assess the Efficacy of AZD2171 45mg Versus Placebo following 12 Weeks of Treatment in Patients with Metastatic or Recurrent Renal Cell Carcinoma who have had no Previous Anti-VEGF Therapy.MedDRA version: 8.1Level: LLTClassification code 10038410Term: Renal cell carcinoma recurrentRenal cell carcinomaEUCTR2006-002455-33-NLAstraZeneca AB105
进行中（未招募）
不适用
A Phase II, Double-blind, Randomised, Parallel Group, Multi-centre Study Comparing gefitinib 250 mg (IRESSA™) with erlotinib 150 mg (Tarceva®) in Previously Treated Patients with Locally Advanced or Metastatic (Stage III or IV) Non-Small Cell Lung Cancer with High Epidermal Growth Factor Receptor Gene Copy Number (EGFR FISH +) - ITEMEUCTR2006-001197-24-DEAstraZeneca AB230
进行中（未招募）
不适用
A Phase II, Double-blind, Randomised, Parallel Group, Multi-centre Study Comparing gefitinib 250 mg (IRESSA™) with erlotinib 150 mg (Tarceva®) in Previously Treated Patients with Locally Advanced or Metastatic (Stage III or IV) Non-Small Cell Lung Cancer with High Epidermal Growth Factor Receptor Gene Copy Number (EGFR FISH +) - ITEMEUCTR2006-001197-24-ATAstraZeneca AB230
进行中（未招募）
不适用
A Phase II, Double-blind, Randomised, Parallel Group, Multi-centre Study Comparing gefitinib 250 mg (IRESSA™) with erlotinib 150 mg (Tarceva®) in Previously Treated Patients with Locally Advanced or Metastatic (Stage III or IV) Non-Small Cell Lung Cancer with High Epidermal Growth Factor Receptor Gene Copy Number (EGFR FISH +) - ITEMon-small Cell Lung CancerEUCTR2006-001197-24-BEAstraZeneca AB230
进行中（未招募）
不适用
A Phase II, Double-blind, Randomised, Parallel Group, Multi-centre Study Comparing gefitinib 250 mg (IRESSA™) with erlotinib 150 mg (Tarceva®) in Previously Treated Patients with Locally Advanced or Metastatic (Stage III or IV) Non-Small Cell Lung Cancer with High Epidermal Growth Factor Receptor Gene Copy Number (EGFR FISH +) - ITEMon-small Cell Lung CancerEUCTR2006-001197-24-GBAstraZeneca AB230